Advancing a Pipeline

Our expanding pipeline of Probody® therapeutics is built on a robust portfolio of proprietary and patented technology. Rooted in innovation and differentiation, and driven by our vision and mission, we are advancing a deep oncology pipeline of Probody therapeutics by blazing our own trail and in partnership with some of the world’s leading biopharmaceutical companies.

Research & development

Product Candidate
LEAD Optimization
Phase 1
Phase 2
+ CX-2009
ER/PR Positive, HER2 Negative Breast Cancer
CD166 Probody drug conjugate (PDC)
CytomX Therapeutics
+ CX-072 +
PD-L1 Probody immunotherapy (IO) + CD166 PDC
CytomX Therapeutics
+ BMS-986249
Metastatic Melanoma
CTLA-4 Probody IO
BMS-986249 - Partner Logo
+ CX-2029
CX-2029 - Partner Logo CytomX Therapeutics
+ BMS-986288
Solid Tumors
CTLA-4 Non-fucosylated Probody IO
BMS-986288 - Partner Logo
+ CX-904
EGFR-CD3 T cell engaging bispecifics (TCB)
CX-904 - Partner Logo CytomX Therapeutics
CytomX Therapeutics
Preclinical<br>CD3-TCB - Partner Logo CytomX Therapeutics
T Cell Bispecific
T Cell Bispecific - Partner Logo CytomX Therapeutics
Additional PDCs, IO, TCBs
CytomX Therapeutics
DLBCL: diffuse large B-cell lymphoma SqHNSCC: squamous head and neck carcinoma SqNSCLC: squamous non small cell lung cancer TNBC: triple negative breast cancer

Lead candidates

We are utilizing our Probody® platform to develop potential best-in-class immunotherapies against clinically validated targets and potential first-in-class therapeutics against novel, difficult-to-treat drug targets. We expect our Probody therapeutics have the potential to:

  • Overcome toxicity challenges associated with many current treatments
  • Enhance the efficacy and safety of combination regimens used to treat cancer
  • Expand the universe of possible drug targets previously considered inaccessible to traditional antibody drug conjugates
  • Offer new more powerful treatment options, especially for patients underserved by current therapies

CX-2009 (CD166-directed Probody drug conjugate)

CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates targeting CD166, have led to complete regressions in models of breast and lung cancer at therapeutically relevant doses, and are well tolerated in non-human primates.

Updated Phase 1 results of CX-2009 in selected tumor types were announced at ASCO 2020  demonstrating durable clinical activity in HER2 negative (HER2-) breast cancer. In December 2019, CytomX initiated a Phase 2 expansion study in patients with hormone receptor (ER, PR) positive, HER2- breast cancer.

CX-072 (PD-L1-targeting Probody therapeutic)

CX-072 is a wholly owned PD-L1-targeting Probody therapeutic for the treatment of cancer. Initial clinical data presented at the ASCO and ESMO 2018 Annual Meetings showed that CX-072 demonstrated tolerability and anti-tumor activity, while reducing activation of the immune system outside the tumor.

Initial clinical translation data presented at SITC confirmed that CX-072 is unmasked, activated and has biological activity in patient tumors while remaining predominantly masked and intact in circulation. Following a recent program and portfolio prioritization, CytomX has also made the strategic decision to terminate the Phase 2 trial of the anti-PD-L1 Probody CX-072 in combination with Yervoy® (ipilimumab) in melanoma. This allows CytomX to focus on its potential first-in-class assets, including the combination of CX-072 and CX-2009.

BMS-986249 (CTLA-4-directed Probody therapeutic)

Bristol Myers Squibb initiated a Phase 2 randomized 5-arm cohort expansion study in its ongoing first-in-human Phase 1/2a trial of the anti-CTLA-4 Probody BMS-986249, a Probody version of the anti-CTLA-4 antibody Yervoy® (ipilimumab), in combination with Opdivo® (nivolumab) in patients with metastatic melanoma (NCT03369223).

CX-2029 (CD71-directed Probody drug conjugate)

CytomX and AbbVie are co-developing CX-2029, a PDC directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. CytomX is evaluating CX-2029 in a Phase 1/2 clinical trial as monotherapy.

CD71 is an excellent “internalizer,” which has the potential to efficiently deliver toxin to tumor cells. Historically, CD71 has not been widely pursued as a target given its expression on normal tissues and potential for causing toxicities. CytomX presented initial Phase 1 data at ASCO 2020 validating CD71 as a first-in-class oncology target with encouraging clinical activity observed. CytomX is preparing to advance the CX-2029 into 4 dose-expansion cohorts in patients with head and neck cancer, squamous non-small cell lung cancer, esophageal carcinoma, and diffuse large B cell lymphoma.

BMS-986288 (CTLA-4-directed Probody therapeutic)

Bristol Myers Squibb is enrolling patients in the dose escalation phase of a Phase 1/2a clinical trial (NCT03994601) of a second anti-CTLA-4 Probody, BMS-986288, based on a modified version of Yervoy® (ipilimumab), to evaluate a CTLA-4-directed Probody therapeutic alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers.

CTLA-4, a clinically validated inhibitory immune checkpoint protein, is the most advanced target from the 12-target collaboration.

CX-904 (EGFR-CD3 T Cell Bispecific)

CytomX and Amgen are developing CX-904, a T-cell engaging bispecific Probody candidate against Epidermal Growth Factor Receptor (EGFR) and CD3. The drug candidate is advancing towards IND-enabling studies.

CytomX is responsible for the IND filing, targeted for late 2021, and for early clinical development with Amgen leading later stage development and commercialization.

CX-188 (PD-1-targeting Probody therapeutic)

CX-188 is our wholly owned PD-1-targeting Probody therapeutic. As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. 

Following a program and portfolio prioritization, CytomX has decided to indefinitely postpone the clinical trials of CX-188, a PD-1 Probody. CytomX may elect to initiate clinical trials of CX-188 in the future.

Clinical trials

Our most promising drug candidates are currently in clinical trials, investigating their potential utility in a number of advanced or recurrent solid tumors or lymphomas.

Learn More

Access information for healthcare providers & patients

Learn More